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Abstract
Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases, with
increasing prevalence affecting millions of people worldwide. Currently, only autopsy is able
to confirm the diagnosis with a 100% certainty, therefore, biomarkers from body fluids
obtained by non-invasive means provide an attractive alternative for the diagnosis of Alzhei-
mer`s disease. Global changes of the protein profile were examined by quantitative proteo-
mics; firstly, electrophoresis and LC-MS/MS were used, thereafter, SRM-based targeted
proteomics method was developed and applied to examine quantitative changes of tear
proteins. Alterations in the tear flow rate, total tear protein concentration and composition of
the chemical barrier specific to AD were demonstrated, and the combination of lipocalin-1,
dermcidin, lysozyme-C and lacritin was shown to be a potential biomarker, with an 81% sen-
sitivity and 77% specificity.
Introduction
Alzheimer’s disease (AD) is one of the most common forms of age-related dementia, affecting
more than 25 million people worldwide, with the number of new cases being continuously on
the rise, particularly in the developed and developing countries [1]. The etiology of AD is still
unknown. The disease can be characterized by massive cognitive decline, occurring in either
sporadic or familial forms. Evidence suggests that abnormal production and accumulation of
misfolded, toxic proteins like β-amyloid (Aβ) peptides, the microtubule-associated protein tau
[2], and the presynaptic protein α-synuclein are involved in the pathogenesis of AD [3]. The
pathological hallmarks of AD are the appearance of senile plaques and neurofibrillary tangles
in the brain tissue, in addition to the development of cerebral amyloid angiopathy, with deposi-
tions of Aβ peptides in the vessel walls [4].
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Based on reported data, AD affects the entire visual system; AD-related changes have been
observed in the eye, the visual pathway, as well as the visual cortex. Aβ depositions in the lens
and retina were also detected, along with changes such as the reduction of the numbers of reti-
nal ganglion cells, thinning of the nerve cell layer, optic atrophy and decline in the numbers of
axons affecting mainly the large diameter axons in the optic nerve [5,6]. These changes result
in the impairment of visual acuity and color vision, defects in fixation, delay in saccadic eye
movement and changes in contrast sensitivity [7].
Multiple studies highlighted the role of Aβ and hyperphosphorylated tau [8] in the patho-
physiology of the disease, however, new evidences suggest the involvement of inflammatory
processes [9] and the increased oxidation of brain proteins [10], besides the amyloid deposi-
tions and neurofibrillary tangle formation. The oxidation of brain proteins is probably the
consequence of higher reactive oxygen species (ROS) production that can be caused by inflam-
matory processes, or by mitochondrial dysfunction, which is often associated with the appear-
ance of AD [11].
Several biomarkers for AD were identified, yet an ideal biomarker that is able to improve
differential diagnosis, track disease progression and measure treatment efficacy has not been
discovered. Despite advances in neuroimaging techniques [12,13], and the opportunities pro-
vided by the “omics” and systems biology studies [14], autopsy remains the only mean to pro-
vide diagnosis with a 100% certainty. Genetic markers; such as mutations in the gene of
amyloid precursor protein (APP), presenilin 1 and 2 (PS1 and PS2) and tau, were identified for
early onset AD, while apolipoprotein E (APOE) and clusterin gene (CLU) mutations were
identified for the late onset form [15,16]. Disease-specific mutations indicating the alteration
of fatty acid and amino acid metabolism, innate immune response, apoptosis, cell communica-
tion, and cell adhesion pathways in the brain of AD patients were also highlighted [17]. For
biomarker analyses, brain tissue, cerebrospinal fluid (CSF), blood plasma and serum were
used, and several candidate protein biomarkers were identified using advanced proteomics
techniques, such as two dimensional gel electrophoresis, oxyblotting, mass spectrometry, and
multiplex assays [14,18].
Selected reaction monitoring (SRM)-based targeted proteomics analysis is a versatile tool
for biomarker studies. SRM is a special scan mode of the triple quadrupole-containing mass
spectrometers, which allows for highly specific identification; and with the help of stable iso-
tope-labeled (SIL) synthetic peptides, it enables the relative or absolute quantification of the
analytes of interest [19,20]. Another advantage of SRM is the multiplex feature, multiple mole-
cules can be analyzed simultaneously from the same sample, which allows for a more cost-
effective analysis compared to the classical antibody-based quantification techniques [21].
With increasing AD prevalence, there is a high demand for novel diagnostic methods utiliz-
ing body fluids collected by non-invasive means, such biomarkers are of valuable importance.
Tear fluid; therefore, provides a viable source, and with its relatively high protein content [22],
it is a widely used candidate for biomarker studies [23–25]. Tear samples are easy to collect,
thus, they provide excellent sample source for developing bedside diagnostic tests for patholog-
ical conditions affecting the ocular system, or the body as a whole [26,27]. The tear fluid creates
a chemical barrier at the surface of the eye as part of the innate immune system, which provides
protection against pathogens by secreting antibacterial and immunomodulatory proteins
(AMPs) that inhibit bacterial growth [28]. The major tear proteins; such as lipocalin-1, lacto-
transferrin and lysozyme-C are involved in the immune and inflammatory processes and
defense against pathogens [22]. The relatively high abundance of these proteins makes them
the major AMPs of tears. Besides the major AMPs, tear fluid contains several prototypic
AMPs, such as defensins, LL-37 cathelicidin in addition to dermcidin [22].
Tear Protein Biomarkers for Alzheimer's Disease
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Tear fluid was used as a potential biomarker source in a study of neuroinflammation in Par-
kinson’s disease; a neurodegenerative condition associated with inflammation, and increased
TNF-α levels were found in tears of PD patients [29].
Considering the extensive influence of AD on the visual system, in this pilot study, we
wanted to examine the changes of tear production, and tear protein composition in patients
with AD and in their age-matched controls. A two-step procedure was applied; firsty, gel-based
LC-MS/MS was used for protein identification on a small sample size, thereafter, an SRM-
based targeted proteomics method was developed for the identified proteins, in order to exam-
ine the AD-dependent alterations on a larger sample size, in order to identify possible tear bio-
markers for AD.
Methods
Sample collection
In total, 23 donors were recruited in this study; 14 patients with AD and 9 age-matched con-
trols. Sample collection complied with the guidelines of the Helsinki Declaration and ethical
approval was obtained from the University of Debrecen Ethics Committee (2980–2009),
while the subjects gave informed written consent. In the case of AD patients, the consent was
acquired in the presence of a caregiver, although none of them were placed under guardianship.
All of the donors were patients of the University of Debrecen, Faculty of Medicine, and the
assessment of AD was done by a psychiatrist. Diagnosis of Alzheimer’s disease was based on
the NINCDS-ADRDA [30] and the DSM-IV-TR [31] criteria. Besides psychiatric and neuro-
logical assessment, patients underwent general medical examination, basic laboratory testing
(blood chemistry analysis, complete blood cell count, hepatic and renal function test, vitamin
B12 and folate level determination, thyroid function test) and CT or MR imaging of the brain to
rule out other causes of dementia. Patients with a history of sudden onset, early extrapyramidal
signs, early behavioral changes or focal neurological features were excluded. The clinical evalu-
ation of the age-matched control subjects consisted of a structured interview, demographic
information, medical history, current medication, history of alcohol consumption and a sub-
jective assessment of memory problems using the Mini-Mental State Examination [32]. Only
controls without any signs of cognitive impairment were included in the study. Patients with
autoimmune disorders, systemic inflammation or ophthalmological disorders were excluded.
In case of AD group, the women to men ratio was approximately 1:2 and the mean age was 77
years, whereas in the control group, the women to men ratio was approximately 1:1 and the
mean age was 72 years. After assessment of the anterior ocular status of each patient, tear was
collected from the inferior meniscus of one or both eyes. The non-traumatic tear collection was
carried out without topical anesthesia using standard capillary collection technique [33], there-
after, collected samples were frozen and stored at -70°C until analysis.
SDS-PAGE
The protein concentration of each tear sample was measured using the Bradford method [34].
20μg tear protein from three randomly selected AD patients and two controls were subjected
to SDS-PAGE analysis on a 10% SDS polyacrylamide gel. Electrophoresis was carried out in a
Bio-Rad mini tetra cell (Bio-Rad) on 100 A constant current for one hour. The protein bands
were stained using Coomassie PageBlue (Fermentas) solution and scanned with a Pharos FX
Plus laser scanner (Bio-Rad). Image analysis was done using the QuantityOne software (Bio-
Rad). Band intensities in each case were determined and statistically analyzed by Mann–Whit-
ney U test using SigmaPlot 12.0 software (Systat Software Inc.).
Tear Protein Biomarkers for Alzheimer's Disease
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LC-MS/MS analysis
Bands with significantly different intensities between AD and control samples were excised,
followed by in-gel digestion with trypsin. Initially, reduction was performed using 20mM
dithiothreitol for one hour at 56°C, followed by alkylation with 55mM iodoacetamide for 45
minutes. Overnight trypsin digestion was carried out using stabilized MS grade TPCK-treated
bovine trypsin (ABSciex) at 37°C, thereafter; the digested peptides were extracted and lyophi-
lized. The peptides were re-dissolved in 10μl 1% formic acid before LC-MS/MS analysis.
Prior to mass spectrometric analysis, peptides were separated using a 90 minute water/ace-
tonitrile gradient, with an increase in acetonitrile concentration from 0 to 100% in a 60 minute
time interval, using an EasynLCII (Bruker) nano HPLC. The peptide mixture was desalted on a
Zorbax 300SB-C18 in-line trap column (5 x 0.3 mm, 5 μm pore size, Agilent), followed by sepa-
ration on a Zorbax 300SB-C18 analytical column (150 mm x 75 μm 3.5 μm pore size, Agilent).
Solvent A was 0.1% formic acid in LC water, solvent B was LC acetonitrile containing 0.1% for-
mic acid, while the flow rate was 300nl/min.
Positive mode LC-MS/MS scans were performed on a 4000 QTRAP (ABSciex) mass spec-
trometer using a NanoSpray II MicroIon source, controlled by the Analyst 1.4.2 software
(ABSciex). The spray voltage was 2800V, the ion source gas was 50 psi, the curtain gas was 20
psi and the source temperature was 70°C. Information Dependent Acquisition method was uti-
lized; after the first mass scan (mass range 400–1700 amu), an enhanced resolution experiment
was carried out to establish the charge state of the precursor ions. The MS/MS spectra of the
two most intensive ions were recorded (mass range 100–1900 amu) in Enhanced Product Ion
mode at a scan rate of 4000 amu/s, and rolling collision energy was applied with the maximum
of 90eV.
The acquired LC-MS/MS data were used for protein identification with the help of Protein-
Pilot 4.0 (ABSciex) search engine searching the SwissProt database (release: 2015.07, 548872
sequence entries), and using the biological modification table included in the ProteinPilot 4.0
software. A minimum of two peptide sequences with95% confidence were used for protein
identification.
Development of SRM-based targeted proteomics experiment
The amino acid sequences of lipocalin-1, lactotransferrin, extracellular glycoprotein lacritin,
lysozyme-C, lipophilin A, Ig λ-chain C region, prolactin inducible protein, Zn-α2 glycoprotein,
galectin 3 binding protein and dermcidin were retrieved from the UniProt database (P31025,
P02788, Q9GZZ8, P61626, P60201, P0CG04, P12273, P25311, Q08380, P81605, respectively),
in silico trypsin digestions were then carried out. In order to determine the unique tryptic
sequences, BLASTp analyses were performed (http://blast.ncbi.nlm.nih.gov), searching the
NCBI non-redundant protein sequence database for unique, protein-specific sequences. The
protein specific sequences were subjected to SRM transition design using the Skyline software
(www.brendanx-uw1.gs.washington.edu). Stable isotope-labeled (SIL) synthetic crude peptides
were obtained from JPT Peptide Technologies GmbH, Germany, and the SRM spectra of all
singly charged “y” ions were registered in case of all peptides. The best two transitions for each
peptide were selected for further analyses.
SRM-based targeted mass spectrometry analysis
37 tear samples originating from 14 AD patients and 9 age-matched controls were denatured
using 6 M urea for 30 mins at room temperature, followed by a digestion procedure similar to
that used for LC-MS/MS sample preparation described above. In the denatured, reduced, and
alkylated samples, the urea concentration was diluted with 25mM ammonium bicarbonate to
Tear Protein Biomarkers for Alzheimer's Disease
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1M immediately before trypsin digestion. Samples were desalted with C18 PierceTips (Thermo
Scientific), lyophilized and re-dissolved in 1% formic acid.
SRM-based analyses of digested tear samples were carried out in triplicates on the 4000
QTRAP mass spectrometer using the same voltage, gas, and temperature, as described above in
section LC-MS/MS analysis. The declustering potential (DP) and collision energy (CE) values
were optimized, and the cycle time was set to 2.5 sec. Chromatographic separation was done
on the EasynLC II, using a 30 min acetonitrile/water gradient with an increase in acetonitrile
concentration from 0 to 100% during a 15 minute time interval.
Sample blocking was carried out before analyzes; a randomly selected AD sample was paired
with a randomly selected control sample and analyzed one after the other using the same con-
ditions. SIL peptides were added to the samples immediately before the analyses. Data were
evaluated using the Skyline software, spectra were examined manually and the AUC values
were calculated by the software. The SRM data were uploaded to the Panorama website:
(https://panoramaweb.org/labkey/project/__r1225/begin.view?) and are publicly available.
The primary AUC data were transformed to MSstats R-package format [35] by an in-house
developed software. After the normalization based on the SIL standard peptides, and log2
transformation of data, group differences were examined by a mixed-effect variance analysis
[36]. Groups were modeled as fixed effect, while the subject level variances were modeled as
random effects. After analysis, the raw p-values were adjusted by the Benjamini and Hochberg
type false discovery rate method for multiple testing purposes [37]. Besides the adjusted p-val-
ues, the log2 fold change, the standard error and the t-values were also examined. Receiver-
operating characteristic (ROC) analyses [38] were carried out by the pROC software [39] and
Confidence Interval (CI) values were calculated.
Results
Tear protein profile changes in AD
The amount of proteins in biological fluids; especially in tear, can provide information of diag-
nostic relevance. The typical protein concentration in tear fluid is 5–7 μg/μl [40], and the tear
production rate is approximately 2 μl/min. Monitoring the tear production rate and tear pro-
tein concentration during sample collection (Table 1), significant differences were observed in
case of AD patients compared to controls. The flow rate of 6 ± 2 μl/min observed in controls
was significantly increased in AD patients (12±2 μl/min), along with a significant increase in
tear protein concentration from 4.4 ± 1.4 μg/μl in controls to 8.8 ± 2.9 μg/μl in AD patients
(Fig 1).
Due to the limited amount of tear fluid; initially, tear profile changes were studied from a
few randomly selected samples, thereafter, validation of the observed differences was carried
out on a larger sample size. In order to monitor global tear protein changes characteristic to
AD, equal amounts of tear proteins from three randomly selected AD patients and two controls
were analyzed by electrophoresis. After visualization of protein bands and carrying out densito-
metric evaluation, 13 bands were observed in each case (Fig 2a), out of which 11 bands showed
a significant decrease in band intensity in AD samples (Fig 2b). The bands were excised and
digested using trypsin, followed by LC-MS/MS based protein identification (Fig 2c, S1 Table).
Only those proteins; of which at least two peptides with95% confidence could be detected,
were accepted as present (S1 Table). Examining the differentially expressed proteins, we have
identified them as being involved in the host defense, and are components of the chemical bar-
rier of the eye. These data suggest that AD can alter the composition of the chemical barrier,
this is in accordance with previous experiments showing alterations of the chemical barrier by
different stimuli and pathological conditions [41–43].
Tear Protein Biomarkers for Alzheimer's Disease
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SRM-based quantitative proteomic method development for tear
proteins
In order to validate changes of the chemical barrier in the tears of AD patients on a larger sam-
ple size, an SRM-based targeted proteomics approach was developed. The SRM scan mode pro-
vides a highly selective and sensitive method to monitor the level of multiple molecules in a
single analysis; however, this method requires the proteins under examination to be defined
priorly. For SRM assay design, lipocalin-1, lactotransferrin, lysozyme-C, extracellular glycopro-
tein lacritin, Ig λ, Zn α2 glycoprotein, prolactin inducible protein and lipophilin A proteins
identified in bands showing significantly different intensity in AD samples as compared to con-
trols were chosen. It is well known that the major proteins of sweat and tears play a role in host
Table 1. Patient data and tear collection parameters.
Patient Nr. Age (years) Gender Tear ﬂow rate (μl/min) Tear protein concentration (μg/μl)
AD 1 67 M OD: 10.0 OD:7.1
AD 2 77 M OD: 12.4
OS: 16.7
OD:3.6
OS:8.3
AD 3 80 F OD: 14.5
OS: 16.7
OD:4.1
OS:3.9
AD 4 80 M OD: 5.0 OD:6.9
AD 5 80 M OS: 5.0 OS:11.5
AD 6 72 F OD: 15.9
OS: 7.7
OD:12.1
OS:14.4
AD 7 90 F OD: 5.6
OS: 13.0
OD:4.8
OS:5.0
AD 8 76 F OD: 11.8 OD:12.1
AD 9 82 M OD: 10.7
OS: 12.7
OD:17.0
OS:15.9
AD 10 81 M OS: 9.6 OS: 9.6
AD 11 65 F OD: 18.1
OS: 18.7
OD:9.4
OS:9.6
AD 12 66 M OD: 10.0
OS: 17.0
OD: 4.7
OS:9.4
AD 13 76 M OD: 14.1
OS: 17.7
OD:9.1
OS:7.5
AD 14 86 M OD: 10.0 OD:8.8
Control 1 73 M OD: 5.0
OS: 0.8
OD:3.5
OS:3.2
Control 2 62 M OD: 10.4
OS: 2.6
OD:4.7
OS:4.7
Control 3 71 M OD: 7.0
OS: 1.2
OD:7.4
OS:7.0
Control 4 71 F OS: 4.6 OS: 3.6
Control 5 81 M OD: 1.2
OS: 8.4
OD:4.4
OS:4.4
Control 6 89 F OD: 3.5
OS: 3.0
OD:2.9
OS:2.3
Control 7 68 F OD: 17.7
OS: 4.6
OD:7.4
OS:6.3
Control 8 66 F OD: 3.2 OD:1.6
Control 9 65 F OD: 6.6 OD:1.4
The eye from which the tear was collected is indicated. OD: Oculus dexter (right eye), OS: Oculus sinister (left eye).
doi:10.1371/journal.pone.0158000.t001
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defense against potential pathogens [22,44], thus, based on previous experiments, galectin-3
binding protein and dermcidin; considered as proteins with an important role in host defense
and immunomodulation [45,46], were also included into the panel of analyzed tear proteins.
SRM-based quantitative proteomic experiments were designed and optimized for the ten
selected proteins (S2 Table). In order to enhance the specificity of the method, stable isotope-
labeled (SIL) synthetic counterparts of the studied peptides were purchased and used in the
analyses as an internal standard (S1 Fig). The sensitivity of the method was assessed by analyz-
ing increasing amounts of SIL peptides added to the tear in a range of 10000 fold– 5 fold dilu-
tion. Most of the peptides were detectable in 10000 fold dilution (approximately 7.5 fmol), and
the SRM signal intensity was proportional to the amount of peptides introduced in a broad
range of dilutions (S3 Table). Based on our results, it appears that the developed SRMmethod
is sensitive enough, and has a broad dynamic range enabling it to be a useful tool to monitor
alterations of tear protein amounts.
Changes in the tear chemical barrier`s composition in AD
The composition of the chemical barrier constantly changes upon different stimuli, as a
response to mechanical and microbial challenges, in order to protect the human organism effi-
ciently from potentially invading pathogens [47]. Moreover, systemic conditions can also affect
the production and secretion of antimicrobial peptides, leading to changes in the composition
of this antimicrobial peptide cocktail [47]. Tear fluid contains a variety of antimicrobial and
immunomodulatory proteins as part of the first line defense of the innate immune system [22].
In order to study changes in the tear`s chemical barrier in AD, level of the ten selected pro-
teins was analyzed using the developed SRMmethod in 37 tear samples from 14 patients with
AD, and 9 controls in triplicates (S4 table). In line with results obtained from electrophoresis,
the levels of lipocalin-1, lactotransferrin, extracellular glycoprotein lacritin, lysozyme-C, and
prolactin inducible protein were significantly decreased, while the level of dermcidin was sig-
nificantly elevated in AD tears, as compared to those of the controls (Fig 3,Table 2). The down-
regulated proteins are expressed by the lacrimal glands, indicating lacrimal gland dysfunction
in AD.
Fig 1. Protein concentration and flow rate of collected tear. The bars represent mean values with the standard error of mean of a) total protein
concentration measured by Bradford method b) tear secretion rate. * indicates p <0.05.
doi:10.1371/journal.pone.0158000.g001
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Identification of potential AD-specific tear biomarkers
Proteins differentially expressed in the tears of AD patients were subjected to further analyses,
in order to examine their potential use as future predictive biomarkers for AD. A receiver oper-
ator characteristic (ROC) analysis was carried out for each significantly expressed protein, and
multivariate ROC curves were constructed to test the different combinations of potential bio-
markers. The sensitivity, specificity, positive and negative predictive values and the area under
the ROC curve (AUC) were calculated in each setting (Table 3). An AUC value close to 1.0
Fig 2. Changes in the tear proteome in AD. a) Gel image of tear proteins from three AD and two control subjects. The left panel shows the
representative band distribution detected with QuantityOne. b) Densitometric analysis of gel bands. The bars showmean values with the standard error of
mean, grey bars indicate control group while the black bars indicate the AD group. * indicates p <0.05. c) List of identified proteins with the corresponding
UniProt reference numbers. * indicates the presence of Ig λ, though the Ig λ-2 chain C region and Ig λ-3 chain C region of the identified peptides were
undistinguishable. LTF: lactotransferrin, ALB: serum albumin, IGHA1: Ig α-1 chain C region, AZGP1: Zn-α2 glycoprotein, KRT1: keratin, type II
cytoskeletal 1, LACRT: extracellular glycoprotein lacritin, KRT10: Keratin, type I cytoskeletal 10, IGLC: Ig λ chain C region, IGKC: Ig κ chain C region,
ZG16B: zymogen granule protein 16 homolog B, PRR4: proline-rich protein 4, LCN1: lipocalin-1, PIP: prolactin-inducible protein, LYZ: lysozyme-C,
LPNC: lipophilin C, LPNA: lipophilin A, CST4: cystatin S.
doi:10.1371/journal.pone.0158000.g002
Tear Protein Biomarkers for Alzheimer's Disease
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indicates a well-performing biomarker; whereas values close to 0.5 suggest a biomarker per-
forming no better than random.
In all cases, the AUC value was above 0.6, and when different combinations of two or more
proteins were analyzed, AUC value was above 0.7, indicating an additive effect of the different
proteins in improving the performance of the test. The highest sensitivity was obtained by
combination of lysozyme-C and extracellular glycoprotein lacritin; yielding 91% sensitivity.
The most balanced performance was achieved when lipocalin-1, dermcidin, lysozyme-C
and extracellular glycoprotein lacritin were combined. In this case, the AUC was 0.80, the
Fig 3. Quantitative analysis of tear proteins by SRM. The log2 fold change of the studied proteins in tears
of patients with AD compared to controls. * indicate p0.05. AZGP1: Zn-α2 glycoprotein, PIP: prolactin-
inducible protein, LYZ: lysozyme-C, LTF: lactotransferrin, LPNA: lipophilin A, LCN1: lipocalin-1, LACRT:
extracellular glycoprotein lacritin, IGLC: Ig λ chain C region, GAL3BP: galectin 3-binding protein, DCD:
dermcidin.
doi:10.1371/journal.pone.0158000.g003
Table 2. Result of the mixed effect variance analysis.
Protein Log2FC SE Tvalue Adjusted p value
Zn-α2 glycoprotein -0.25 0.17 -1.43 0.26
Prolactin-inducible protein -0.66 0.14 -4.75 <0.0001
Lysozyme-C -1.11 0.15 -7.29 <0.0001
Lipophilin A 0.09 0.23 0.39 0.76
Lipocalin-1 -0.76 0.13 -5.79 <0.0001
Lactotransferrin -1.16 0.17 -6.66 <0.0001
Ig λ chain C region -0.27 0.23 -1.19 0.35
Galectin 3-binding protein 0.13 0.19 0.68 0.59
Extracellular glycoprotein lacritin -2.04 0.18 -11.53 <0.0001
Dermcidin 0.85 0.23 3.64 0.0006
The log2 fold change (log2FC) standard error (SE), T values (Tvalue) and the FDR corrected p-values are shown.
doi:10.1371/journal.pone.0158000.t002
Tear Protein Biomarkers for Alzheimer's Disease
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sensitivity was 81% and the specificity was 77%. Considering these values, it seems that a test
combining these four potential biomarkers may therefore be used as a first screen in the diag-
nosis of AD.
Discussion
Tear fluid is an excellent candidate for biomarker studies, given the facts that samples may be
collected non-invasively, in addition to providing information not only on local ocular condi-
tions; such as dry-eye disease and diabetic retinopathy, but also on systemic pathophysiological
processes [22,25,29]. The presence of amyloid plaques was demonstrated in the retina and lens
of patients with Alzheimer’s disease, and animal model studies indicated correlation in amyloid
depositions between the retina and the brain [5,6]. Changes in the retinal vasculature and reti-
nal morphology were detected in the eyes of patients with AD, resulting in the reduced visual
performance observed in AD patients [13]. We have hypothesized that changes in retinal mor-
phology and blood flow related to AD may alter the microenvironment of the eye, and this
alteration may therefore be reflected at the level of tear proteins.
In our study, a significant increase in the flow rate and protein concentration, along with a
significant difference in the amount of the studied tear proteins was observed in samples
obtained from AD patients. This is in good agreement with previously published data suggest-
ing extensive ocular alterations related to AD [5–7]. The protein level changes observed with
electrophoretic analysis of five samples were validated by targeted proteomics analyses on 37
samples. The only increase in tear proteins characteristic to AD has been observed in case of
dermcidin, which is produced by epithelial cells, [47] and is the main sweat antimicrobial pep-
tide with a broad range antimicrobial activity [44]. The proteins with reduced amount were
involved in first line defense of the eye, produced by the lacrimal gland.
The altered composition of the chemical barrier, along with the reduced level of studied
defense proteins might imply an increased risk of ocular infections, yet there has been no
reported increase of ocular infections in patients with AD according to the scientific literature.
Table 3. ROC analysis of possible tear biomarkers for AD.
Proteins Sensitivity (%) Speciﬁcity (%) PV+ (%) PV- (%) AUC Accuracy 95% CI
LCN1 53.1 79.7 22.7 43.3 0.68 0.72 0.56–0.80
LTF 78.1 51.6 17.5 55.4 0.67 0.73 0.55–0.78
LYZ 90.6 50 8.6 52.5 0.68 0.67 0.57–0.79
PIP 71.9 56.2 20 54.9 0.6 0.67 0.48–0.72
LACRT 90.6 57.8 7.5 48.2 0.71 0.65 0.59–0.82
DCD 62.5 76.6 19.7 42.9 0.7 0.70 0.59–0.82
LCN1+DCD 53.1 89.1 20.8 29.2 0.74 0.76 0.63–0.85
LYZ+LACRT 90.6 59.4 7.3 47.3 0.72 0.64 0.61–0.83
LCN1+DCD+ LACRT 90.6 65.6 6.7 43.1 0.8 0.69 0.71–0.89
LCN1+DCD+LTF 53.1 89.1 20.8 29.2 0.74 0.76 0.62–0.84
LCN1+DCD+LYZ 59.4 82.8 19.7 36.7 0.75 0.76 0.64–0.86
LCN1+LTF+LYZ 87.5 50 11.1 53.3 0.72 0.71 0.61–0.83
LYZ+LACRT+ DCD 90.6 65.6 6.7 43.1 0.79 0.71 0.69–0.89
LYZ+LACRT+ LCN1 87.5 59.4 9.5 48.1 0.72 0.67 0.62–0.83
PIP+LACRT+DCD 93.8 60.9 4.9 45.5 0.79 0.68 0.69–0.97
DCD+LCN1+LTF+PIP 62.5 76.6 19.7 42.9 0.74 0.72 0.64–0.84
LCN1+DCD+LYZ+LACRT 81.2 76.6 10.9 36.6 0.8 0.72 0.71–0.89
doi:10.1371/journal.pone.0158000.t003
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However, reduced corneal sensitivity and abnormal tear functions were reported in AD
patients as compared to controls, in addition to other neurodegenerative diseases [48]. Dermci-
din; with its broad antimicrobial spectrum, appears to be a plausible factor responsible for lim-
iting bacterial over-growth and; therefore, possible infections.
Given the easy, non-invasive collection possibility of tears, the prospect of a bedside test
development is worth exploring. Patients with an increased tear flow rate (above 5 μl/min
according to our data), along with increased tear protein concentration, and who also show
altered level of extracellular glycoprotein lacritin, lipocalin-1, lysozyme-C and dermcidin, may
be subjected to further imaging, neuropsychological testing (CT, MRI, PET) and cerebrospinal
fluid analyses (Aβ42, total tau and p-tau levels). Considering the small sample size analyzed in
this pilot study, more studies carried out on a large population scale are required, in order to
evaluate the applicability of the proposed biomarkers. After validation, tear analysis, as an eas-
ily executable test, can be used in population screening by general practitioners, and patients
with a positive test may be further evaluated by clinical centers for the establishment of the
diagnosis. If early diagnosis and treatment are promptly provided, the quality of life can be
improved for AD patients and their caregivers, which will undoubtedly aid in decreasing the
socio-economic burden of the disease.
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